A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]

SUPPORT RESOURCES Booklets, Brochures, Fact Sheets and Inserts English Resources Booklets & Fact Sheets Drug Treatments This four-page fact sheet focuses on medications used to treat osteoporosis. Contains detailed information […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

Romosozumab EVENITY™ (romosozumab injection) Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.Romosozumab (EVENITY™) significantly and rapidly (over […]

Board of Directors Jeannette Briggs Chair | Oakville, ON Jeannette has more than 25 years of experience working in the energy sector.  She has held a wide-range of jobs within […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Members of Osteoporosis Canada’s Scientific Advisory Council would like announce this year’s Lindy Fraser Award winner as chosen by the members of the SAC. Osteoporosis Canada established this award in 1993 […]